



Drug Information Service

Intravenous Solution Conservation Strategies

(Compiled by the American Society of Health-System Pharmacists and the University of Utah Drug Information Service, March 20, 2014)

Introduction

This fact sheet summarizes the status of the current acute shortage of certain large-volume intravenous solutions and provides a list of potential actions to conserve them that organizations might consider to manage the shortage. Healthcare professionals should use their professional judgment in deciding how to use the information in this document, taking into account the needs and resources of their individual organizations.

Why is Conservation Necessary?

There is a national shortage of 0.9% Sodium Chloride Injection, 0.45% Sodium Chloride Injection, Lactated Ringer's Injection, and 5% Dextrose Injection that is not expected to resolve until May or June, 2014. Products most affected by this shortage are large-volume (i.e., 1000 mL) bags.

What can clinicians do to conserve?

- Use oral hydration whenever possible.
- Review the suggested clinical approaches and product conservation strategies in collaboration with the organization's stakeholders and the Pharmacy and Therapeutics (P&T) Committee or other organization-wide medication policy group for applicability to the organization.
- Implement an organization-specific action plan to conserve IV fluids where possible. Allow flexibility as the shortage status of specific products may change frequently. For example, Lactated Ringer's Injection may be more available than 0.9% Sodium Chloride Injection and vice-versa depending product availability and allocation schedules.
- Develop medical staff-approved policies for substitution of IV solutions based on product availability within the organization. Example: an organization might allow substitution of Lactated Ringer's Injection for 0.9% Sodium Chloride Injection or vice-versa depending on what is in stock. Table 1 provides a comparison of common intravenous fluid components.

Patient Clinical Evaluation

- Frequently, or at minimum once each shift, evaluate the clinical need to continue intravenous fluid therapy. Consider identifying specific clinical personnel to actively monitor usage for each patient.
- Discontinue infusions as soon as appropriate. Consider stop orders for infusions, for example 24–48 hour automatic stops, if not reordered.
- Frequently, or at minimum once each shift, assess need to continue "keep vein open" (KVO) orders.
- Consider locking catheters rather than infusing 0.9% sodium chloride injection at a KVO rate when possible.

- Consider flushing central venous access devices (CVADs) 1–3 times per week rather than daily.
- Evaluate total fluid requirements for surgeries. The American College of Surgeons: Principles and Practice 2014 notes that total volume replacement needs for elective surgeries are much less (500 mL to 3000 mL total) than previously thought (4500 mL to 6000 mL total).¹

Product Conservation

- Use small-volume bags for low infusion rates (see <u>Table 2</u>).
- Consider reserving some products for specific clinical situations. <u>Table 3</u> outlines potential suggestions, but is not inclusive of all possible actions.
- Consider deferring elective procedures and surgeries requiring 0.9% Sodium Chloride Injection or other solutions in short supply.
- Consider hang times longer than 24 hours for solutions (if infusion is spiked immediately prior to administration). There is no nationally published guideline recommending a maximum hang time for an infusion. If longer hang times are used, hospital leadership; medical, nursing and pharmacy staff; infection control; risk management; and other stakeholders should weigh the risk of infection against the need to conserve intravenous solutions. Note: hang times should not exceed manufacturers' instructions, if available, or beyond-use dating assigned according to USP-NF Chapter <797>, Compounding Sterile Preparations for compounded solutions.
- Evaluate the clinical practice of using flush bags for intermittent medications when no primary solution is being administered. 0.9% Sodium Chloride flush syringes are an alternative.
- Use commercially available dialysis solutions whenever possible, instead of compounding with 0.9% sodium chloride.

Inventory Control Strategies

- Evaluate IV fluid supplies on a health system-wide basis in order to redeploy solutions to areas of greatest need.
- Minimize unit stock of large-volume bags to the extent possible or stock product only in critical care areas where fluids are an essential component of emergency supplies.
- Ensure smaller volume bags are stocked in other supply areas, especially pediatric areas.
- Limit quantities of bags placed in warmers.
- Ensure purchasing agents have active backorders in place and are obtaining allocations as available.
- Frequently communicate with distributor as allocations and shipment dates may be unpredictable.
- Establish routine conference calls or meetings among stakeholders to discuss supply status before supplies become critically low.
- Avoid buying products from sources outside the traditional supply chain. Report suspected illegal
 activity by nontraditional distributors to the state board of pharmacy, state attorney general, or
 <u>FDA's Office of Criminal Investigation.</u>
- Provide regular or as needed updates on shortage status and action plan adjustments to clinicians and other organizational stakeholders (e.g., risk management/patient safety, leadership, etc.)
- The use of multiple communication methods is highly recommended.

Caveats / Safety information

- Compounding sodium chloride solutions from sterile water for injection and concentrated sodium chloride injection is error-prone, labor-intensive, and may worsen the existing shortage of concentrated sodium chloride injection. In addition, the high-volume of product needed to meet patient needs makes compounding impractical. Compounding should be limited to solutions needed to meet urgent short-term needs for sodium and fluid replacement therapy, when commercial products are unavailable.
- Reflect use of smaller volumes in infusion pump libraries, pre-printed or electronic order sets, and standard IV fluid labels as needed.
- Avoid intravenous use of sodium chloride irrigation solution. Sterility requirements and limits on particulate matter differ between these two products.

Product	mOsm /L	Na (mEq/L)	Cl (mEq/L)	Dextrose (g/L)	K (mEq/L)	Ca (mEq/L)	Lactate (mEq/L)	Mg (mEq/L)	Acetate (mEq/L)	Gluconate (mEq/L)
0.9% Sodium	308	154	154							
Chloride										
Injection										
0.45%	154	77	77							
Sodium										
Chloride										
Injection										
5% Dextrose	329	38.5	38.5	50						
and 0.225%										
Sodium										
Chloride										
Injection										
5% Dextrose	406	77	77	50						
and 0.45%										
Sodium										
Chloride										
Injection										
5% Dextrose	560	154	154	50						
and 0.9%										
Sodium										
Chloride										
Injection										
5% Dextrose Injection	252			50						
Lactated	273	130	109		4	2.7	28			
Ringer's										
Injection										
Lactated	525	130	109	50	4	2.7	28			
Ringer's and										
5% Dextrose										
Injection										
Normosol-R	294	140	98		5			3	27	23
Plasma-lyte A	294	140	98		5			3	27	23

Table 1. Comparison of Selected Intravenous Fluids²⁻⁷

Table 2. Recommended Container Volumes Based on Infusion Rates

Infusion Rate	Bag Size		
20 mL/hour or less	250 mL		
21 mL/hour to 40 mL/hour	500 mL		
41 mL/hour or greater	1000 mL		

Table 3. Considerations for Reserving Products for Selected Clinical Situations⁸⁻¹¹

Clinical Situation	Product	Comments			
Large volume replacement	Lactated Ringer's	Large volumes of 0.9% sodium chloride may			
(surgery)	Injection	contribute to hyperchloremic acidosis.			
Patients requiring sodium	Products containing	Consider reserving a supply of fluids with			
restriction	Dextrose 5% Injection	lower sodium content for these patients.			
Patients susceptible to	Products containing	Women and children may be more			
hypoglycemia	Dextrose 5% Injection	susceptible to hypoglycemia following fasts			
		> 24 hours.			
Pediatric patients requiring	0.9% Sodium chloride	Pediatric patients are susceptible to water			
volume replacement	Injection	intoxication and hyponatremia if sodium			
		chloride replacement is inadequate.			

References

- Evolution of Intraoperative Fluid Therapy for Elective Surgeries: Historical and Current Fluid Requirements. In: Souba WW, Fink MP, Jurkovich GJ, Kaiser LR, Pearce WH, Pemberton JH, Soper NJ. ACS Surgery: Principles and Practice 2014. Accessed March 1, 2014 via STAT!Ref Online Electronic Medical Library. <u>http://online.statref.com/Document.aspx?fxld=61&docld=158</u>.
- Hospira. Lactated Ringer's Injection USP, Lactated Ringer's and 5% Dextrose Injection, USP [product information]. Lake Forest, IL: Hospira; 2009.
- 3. Hospira. Dextrose and Sodium Chloride Injection, USP [product information]. Lake Forest, IL: Hospira; 2009.
- 4. Hospira. Sodium Chloride Injection, USP [product information]. Lake Forest, IL: Hospira; 2010.
- 5. Hospira. Dextrose Injection, USP [product information]. Lake Forest, IL: Hospira; 2010.
- 6. Hospira. Normosol-R [product information] Lake Forest, IL: Hospira; 2009.
- 7. Baxter. Plasma-Lyte A [product information]. Deerfield, IL: Baxter; 2013.
- 8. Intravenous Fluids. In: Morgan GE, Michail MS, Jurray MJ, eds. *Clinical Anesthesiology*. 4th ed. New York, NY: Lange Medical Books / McGraw-Hill Medical; 2005: 692-6.
- 9. Peng ZY, Kellum JA. Perioperative fluids: a clear road ahead? Curr Opin Crit Care. 2013 Aug;19(4):353-8.
- 10. Raghunathan K, Shaw AD, Bagshaw SM. Fluids are drugs: type, dose and toxicity. *Curr Opin Crit Care.* 2013 Aug;19(4):290-8.
- 11. Institution for Safe Medication Practices Medication Safety Alert: Regarding the Current IV Solution Shortage Affecting U.S. Hospitals. 2014 Jan 30. <u>http://www.ismp.org/newsletters/acutecare/showarticle.aspx?id=69</u> Accessed March 9, 2014.

This information was developed by the Drug Information Center of University of Utah in collaboration with the American Society of Health-System Pharmacists. ASHP and the University of Utah neither endorse nor recommend the strategies for the use of any drug or product, nor assume any liability for persons providing medications or other medical care in reliance upon this information. Users of this information must exercise their independent professional judgment when using this information to make decisions regarding the use of drugs and drug therapies.